Abstract
Vopratelimab, an anti-ICOS(inducible costimulator of T cells) agonist, alone and in combination with nivolumab, possesses limited toxicity and modest ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
